Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

07-10-2014 | Gastric cancer | Article

Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative

Journal: Annals of Surgical Oncology

Authors: Yuhree Kim, MD, Aslam Ejaz, MD, Gaya Spolverato, MD, Malcolm H. Squires, MD, George Poultsides, MD, Ryan C. Fields, MD, Mark Bloomston, MD, Sharon M. Weber, MD, Konstantinos Votanopoulos, MD, Alexandra W. Acher, BE, Linda X. Jin, BS, William G. Hawkins, MD, Carl Schmidt, MD, David Kooby, MD, David Worhunsky, MD, Neil Saunders, MD, Clifford S. Cho, MD, Edward A. Levine, MD, Shishir K. Maithel, MD, Timothy M. Pawlik, MD, MPH, PhD

Publisher: Springer US

Login to get access

Abstract

Background

Survival estimates following surgical resection of gastric adenocarcinoma are traditionally reported as survival from the date of surgery. Conditional survival (CS) estimates, however, may be more clinically relevant by accounting for time already survived. We assessed CS following surgical resection for gastric adenocarcinoma.

Methods

We analyzed 807 patients who underwent resection for gastric adenocarcinoma from 2000 to 2012 at seven participating institutions in the U.S. Gastric Cancer Collaborative. Cox proportional hazards models were used to evaluate factors associated with overall survival. Three-year CS estimates at “x” year after surgery were calculated as follows: CS3 = S(x+3)/S(x).

Results

Overall 1-, 3-, and 5-year overall survival rates after gastric resection were 42, 34, and 30 %, respectively. Using CS estimates, the probability of surviving an additional 3 years given that the patient had survived at 1, 3, and 5 years were 56, 71, and 82 %, respectively. Patients with higher risk at baseline (i.e., stage III or IV disease, lymphovascular invasion) demonstrated the greatest increase in CS over time.

Conclusions

Survival estimates following surgical resection of gastric adenocarcinoma is dynamic; the probability of survival increases with time already survived. Patients with worse prognostic features at the time of surgery had the greatest increases in CS over time. Conditional survival estimates provide important information about the changing probability of survival over time and should be used among patients with resected gastric adenocarcinoma to guide subsequent follow-up strategies.
Literature
1.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.PubMedCentralPubMed
3.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef
4.
Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRef
5.
Arrington AK, Nelson R, Patel SS, et al. Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World J Gastrointest Surg. 2013;5(12):321–8.PubMedCentralPubMedCrossRef
6.
Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23–31.PubMedCrossRef
7.
Miceli R, Tomasello G, Bregni G, et al. Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World J Gastroenterol. 2014;20(16):4516–25.PubMedCentralPubMedCrossRef
8.
Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol. 2013;20(7):2328–38.PubMedCrossRef
9.
Kim JP, Lee JH, Kim SJ, et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1(2):125–33.PubMedCrossRef
10.
Isozaki H, Okajima K, Fujii K, et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology. 1999;46(25):549–54.PubMed
11.
Berardi R, Scartozzi M, Romagnoli E, et al. Gastric cancer treatment: a systematic review. Oncol Rep. 2004;11(4):911–6.PubMed
12.
Dickson JL, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol. 2004;16(3):255–63.PubMedCrossRef
13.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMedCrossRef
14.
Dikken JL, Baser RE, Gonen M, et al. Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer. Ann Surg Oncol. 2013;20(5):1623–30.PubMedCentralPubMedCrossRef
15.
Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer. 2014;17(2):287–93.PubMedCrossRef
16.
Merrill RM, Henson DE, Ries LA. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum. 1998;41(9):1097–106.PubMedCrossRef
17.
Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. Cancer. 1995;76(2):237–42.PubMedCrossRef
18.
Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210(5):755–64, 764–6.
19.
Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol, 2003;21(16):3035–40.PubMedCrossRef
20.
Sun M, Trinh QD, Karakiewicz PI. Conditional survival of patients with metastatic renal-cell carcinoma. Lancet Oncol. 2012;13(11):e462.PubMedCrossRef
21.
Wang SJ, Emery R, Fuller CD, et al. Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer. 2007;10(3):153–8.PubMedCrossRef
22.
Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118(10):2674–81.PubMedCentralPubMedCrossRef
23.
Ito Y, Nakayama T, Miyashiro I, et al. Conditional survival for longer-term survivors from 2000-2004 using population-based cancer registry data in Osaka, Japan. BMC Cancer. 2013;13:304.CrossRef
24.
Lee SE, Ryu KW, Nam BH, et al. Prognostic significance of intraoperatively estimated surgical stage in curatively resected gastric cancer patients. J Am Coll Surg. 2009;209(4):461–7.PubMedCrossRef
25.
Deng J, Liang H, Wang D, et al. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41(2):210–5.PubMedCrossRef
26.
Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003;27(2):153–8.PubMed
27.
Huang KH, Chen JH, Wu CW, et al. Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol. 2009;24(9):1522–6.PubMedCrossRef
28.
Sakar B, Karagol H, Gumus M, et al. Timing of death from tumor recurrence after curative gastrectomy for gastric cancer. Am J Clin Oncol. 2004;27(2):205–9.PubMedCrossRef
29.
Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21(19):3647–50.PubMedCrossRef
30.
Posteraro B, Persiani R, Dall’Armi V, et al. Prognostic factors and outcomes in Italian patients undergoing curative gastric cancer surgery. Eur J Surg Oncol. 2014;40(3):345–51.PubMedCrossRef
31.
Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg. 2006;243(1):64–73.PubMedCentralPubMedCrossRef
32.
Dicken BJ, Saunders LD, Jhangri GS, et al. Gastric cancer: establishing predictors of biologic behavior with use of population-based data. Ann Surg Oncol. 2004;11(6):629–35.PubMedCrossRef
33.
Duraker N, Sisman S, Can G. The significance of perineural invasion as a prognostic factor in patients with gastric carcinoma. Surg Today. 2003;33(2):95–100.PubMedCrossRef
34.
Bilici A, Seker M, Ustaalioglu BB, et al. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection. Ann Surg Oncol. 2010;17(8):2037–44.PubMedCrossRef
35.
Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014;21(5):1678–85.PubMedCrossRef
36.
Kim BS, Oh ST, Yook JH, Kim BS. Signet ring cell type and other histologic types: differing clinical course and prognosis in T1 gastric cancer. Surgery. 2014;155(6):1030–35.
37.
Polley MY, Lamborn KR, Chang SM, et al. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011;29(31):4175–80.PubMedCentralPubMedCrossRef
38.
Choi M, Fuller CD, Thomas CR Jr, Wang SJ. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol. 2008;109(2):203–9.PubMedCrossRef